Male breast cancer is rare but real, and knowing when and how to get tested can make all the difference. Understanding the diagnostic process helps men recognize warning signs early and seek proper medical evaluation.

Introduction: Who Should Seek Diagnostic Testing

While breast cancer is often thought of as a condition affecting only women, men can develop it too. Because everyone is born with some breast tissue, anyone can get breast cancer, though it happens much less frequently in men^[1]. About one out of every 100 breast cancer cases diagnosed in the United States occurs in men^[2]. This rarity can make it easy for men to dismiss concerning symptoms, but early detection is crucial for successful treatment.

Men should seek medical evaluation if they notice any unusual changes in their chest area. The most common sign is a firm, painless lump in one of the breasts, typically located behind the nipple^[3]. Other warning signs include a lump in the armpit, skin changes on the chest such as dimpling or pitting that resembles orange peel, red or flaky skin near the breast or nipple, pain or tenderness in the chest or underarm area, nipple discharge or bleeding, or a nipple that begins to turn inward^[1][2]. These symptoms can occur with conditions other than cancer, but it’s important not to ignore them.

Because male breast cancer is so uncommon, men may delay seeking medical attention, assuming a lump is harmless. This delay can lead to diagnosis at a later stage when the cancer has grown or spread^[3]. One reason men are often diagnosed later than women is that they may be less likely to report signs and symptoms, which leads to delays in getting the proper tests^[5]. If you notice any of these changes, schedule an appointment with your doctor right away, even if you think it’s probably nothing serious.

Men at higher risk for breast cancer should be especially vigilant about symptoms. Risk factors include getting older (most cases are diagnosed after age 50), having a close family member with breast or ovarian cancer, carrying genetic mutations such as BRCA1 or especially BRCA2, having conditions that raise estrogen levels like liver disease or Klinefelter syndrome, having received radiation therapy to the chest, being overweight or obese, or having been treated with estrogen-containing drugs in the past^[2][3]. If several members of your family have had breast or ovarian cancer, or if a family member has a known BRCA1 or BRCA2 mutation, share this information with your doctor, who may refer you for genetic counseling^[2].

Classic Diagnostic Methods

When a man presents with symptoms that suggest breast cancer, doctors use several tests to diagnose the condition and distinguish it from other problems. The diagnostic process typically begins with a clinical breast exam, during which a healthcare professional carefully feels the breasts and surrounding areas for lumps or other changes^[11]. During this exam, the doctor assesses how large any lumps are, how they feel, and how close they are to the skin and muscles. This physical examination helps determine which additional tests are needed.

Imaging tests are a crucial next step in diagnosis. These tests create pictures of breast tissue to look for signs of cancer^[11]. Mammography, which is a breast X-ray, is commonly used when breast cancer is suspected. For men aged 25 years or older, or those with highly concerning physical examination findings, mammography is recommended as the initial imaging test^[12]. For younger men under 25, an ultrasound is often performed first because breast cancer is highly unlikely in this age group, and ultrasound uses sound waves rather than radiation. If ultrasound findings are suspicious, a mammogram may follow^[12].

An ultrasound creates real-time pictures of the inside of the body using sound waves. It can help distinguish between solid lumps and fluid-filled cysts, and it’s particularly useful for examining dense breast tissue. Sometimes an MRI scan (magnetic resonance imaging) is also used. This test uses magnets and radio waves to create detailed images of the breast tissue and can provide additional information about suspicious areas^[11].

If imaging tests reveal suspicious findings, the next step is usually a biopsy. This is the only way to definitively determine whether cells are cancerous. During a biopsy, a healthcare professional removes a small sample of breast cells for examination in a laboratory^[11]. The most common type is a core biopsy, in which a needle is inserted through the skin of the chest to extract tissue samples. The doctor guides the needle using mammogram images or another imaging test to ensure the sample is taken from the right location. This procedure is generally done with local anesthesia to numb the area.

Once tissue samples are obtained, laboratory specialists examine the cells under a microscope to determine if they are cancerous. If cancer is present, additional tests are performed on the biopsy sample to learn more about the cancer’s characteristics. These tests include checking the hormone receptor status, which reveals whether the cancer cells have receptors that respond to hormones like estrogen and progesterone^[12]. Most male breast cancers are estrogen receptor-positive, meaning they have receptors that cause cancer cells to grow when exposed to estrogen^[3].

Another important test checks the HER2 status, which tells doctors whether the cancer cells have a protein called human epidermal growth factor type 2 (HER2) on their surface^[12]. This protein can cause cancer cells to grow more quickly, and knowing the HER2 status helps determine which treatments might work best. These molecular characteristics of the cancer cells are crucial for creating an effective treatment plan.

Staging Tests After Diagnosis

If breast cancer is confirmed, doctors need to determine how far it has spread. This process is called staging, and it helps predict prognosis and guide treatment decisions^[11]. Staging often involves additional imaging tests to check whether cancer has spread beyond the breast to other parts of the body, such as the lymph nodes, bones, lungs, liver, or brain.

Common staging tests include a bone scan, which uses a small amount of radioactive material to identify areas where cancer may have spread to bones. A CT scan (computed tomography) uses X-rays taken from different angles to create detailed cross-sectional images of organs and tissues. A PET scan (positron emission tomography) can detect cancer cells throughout the body by showing areas of high metabolic activity, which is characteristic of cancer^[11].

The histopathologic classification identifies the type of breast cancer present. The most common type in men is infiltrating ductal carcinoma, also called invasive ductal carcinoma, which means cancer has spread beyond the cells lining the ducts in the breast^[7]. This accounts for up to 9 out of 10 male breast cancers^[3]. Less commonly, men may have ductal carcinoma in situ (DCIS), where abnormal cells are found only in the lining of a duct and haven’t spread beyond it^[7]. Other rare types include inflammatory breast cancer, where the breast looks red and swollen, and Paget disease of the nipple, where a tumor has grown from ducts beneath the nipple onto its surface^[7].

Diagnostics for Clinical Trial Qualification

When men with breast cancer consider participating in clinical trials, they typically undergo specific diagnostic tests to determine if they meet the trial’s eligibility criteria. Clinical trials test new treatments or combinations of treatments, and researchers need to ensure that participants have specific characteristics to properly evaluate the experimental approaches.

The standard diagnostic tests used for clinical trial qualification generally include the same tests used for initial diagnosis and staging. Participants must have confirmed breast cancer through biopsy results that show malignant cells^[11]. The biopsy tissue is examined not just to confirm cancer, but to determine its molecular features, which are often key criteria for trial enrollment.

Hormone receptor testing is particularly important for many clinical trials. Researchers need to know whether the cancer is estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), or hormone receptor-negative. Since most male breast cancers are hormone receptor-positive, many trials studying hormone therapy treatments specifically seek participants with this characteristic^[12]. HER2 status testing is equally crucial, as some trials focus on therapies targeting HER2-positive cancers while others enroll only HER2-negative patients.

Imaging tests establish the stage of cancer, which determines eligibility for different trials. Some trials accept only early-stage breast cancer patients, while others focus on metastatic cancer that has spread to other organs. Complete staging through mammography, ultrasound, CT scans, bone scans, or PET scans documents the extent of disease spread^[11]. These imaging results must be recent, often obtained within weeks before trial enrollment, to ensure accurate staging information.

Blood tests are also standard requirements for clinical trial qualification. These include general health assessments such as complete blood counts to measure red and white blood cells and platelets, liver function tests to check how well the liver is working, and kidney function tests to assess kidney health. These tests ensure that participants are healthy enough to tolerate the experimental treatments and that their organs can properly process the medications being studied.

Some trials require genetic testing to identify specific mutations or gene changes that might affect how patients respond to treatment. For example, trials studying treatments for patients with BRCA mutations would require documented genetic testing showing the presence of BRCA1 or BRCA2 mutations^[7]. Other trials might look for different genetic markers that suggest a cancer will respond to particular targeted therapies.

Performance status assessments are another qualification criterion for most trials. Doctors evaluate how well patients can perform daily activities and how much the cancer affects their physical functioning. This helps ensure that participants can safely undergo the experimental treatments and complete the trial protocol. The assessment considers factors like energy levels, ability to care for oneself, and amount of time spent resting versus active.

Documentation of previous treatments is also required for clinical trial enrollment. Researchers need complete records of any prior surgeries, chemotherapy, radiation therapy, hormone therapy, or other treatments the patient has received. Some trials specifically enroll patients who have not yet received treatment, while others focus on those whose cancer has returned after initial treatment or who have not responded to standard therapies.